1. Home
  2. HTGC vs LQDA Comparison

HTGC vs LQDA Comparison

Compare HTGC & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hercules Capital Inc.

HTGC

Hercules Capital Inc.

HOLD

Current Price

$16.41

Market Cap

3.2B

Sector

Finance

ML Signal

HOLD

LQDA

Liquidia Corporation

HOLD

Current Price

$43.74

Market Cap

3.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HTGC
LQDA
Founded
2003
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.2B
3.8B
IPO Year
2004
2020

Fundamental Metrics

Financial Performance
Metric
HTGC
LQDA
Price
$16.41
$43.74
Analyst Decision
Strong Buy
Buy
Analyst Count
9
8
Target Price
$19.50
★ $54.38
AVG Volume (30 Days)
1.0M
★ 5.2M
Earning Date
10-29-2026
11-06-2026
Dividend Yield
★ 11.46%
N/A
EPS Growth
14.91
★ 51.81
EPS
0.90
★ 1.26
Revenue
N/A
★ $158,320,000.00
Revenue This Year
$9.32
$357.27
Revenue Next Year
$7.07
$1.34
P/E Ratio
★ $18.19
$33.88
Revenue Growth
N/A
★ 1031.18
52 Week Low
$13.70
$22.05
52 Week High
$19.13
$93.61

Technical Indicators

Market Signals
Indicator
HTGC
LQDA
Relative Strength Index (RSI) 44.57 50.31
Support Level $16.09 $35.00
Resistance Level $17.05 $46.67
Average True Range (ATR) 0.27 2.98
MACD 0.01 2.63
Stochastic Oscillator 58.61 93.07

Price Performance

Historical Comparison
HTGC
LQDA

About HTGC Hercules Capital Inc.

Hercules Capital Inc is a specialty finance company focused on providing senior secured loans to high-growth, venture capital-backed, and institutional-backed companies in a variety of technology and life sciences industries. The company's primary business objectives are to increase its net income, net investment income, and net asset value (NAV) through its investments mainly in structured debt or senior secured debt instruments of venture capital-backed and institutional-backed companies across a variety of technology-related industries at attractive yields. It finances companies belonging to computer software and hardware, networking systems, semiconductors, medical devices, bio-pharmaceutical, and other related sectors.

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.

Share on Social Networks: